Search results
-
ASCO-GI – Astellas focuses on a degrader-chemo combo
… which initially reported disappointing results at ESMO 2024 from the same phase 1 trial. Phase 1 …
- 01/13/2026 - 13:49 -
HengRui goes pivotal in KRAS G12D
… stages. That project initially failed to impress at ESMO 2024, but produced more promising efficacy results in …
- 12/02/2025 - 13:31 -
Nuvalent presses ahead in ALK
… ALKi Post Lorbrena Phase 1 part (ESMO 2024) Patients NA 103 17 85 …
- 11/18/2025 - 14:23 -
Gastrointestinal is next for pumitamig
… same setting, ivonescimab plus chemo produced an 82% ORR at ESMO 2024. Meanwhile, the Rosetta Gastric-204 trial will …
- 11/11/2025 - 14:36 -
Triple meeting 2025 – Astellas touts a degrader turnaround
… At ESMO 2024, Astellas’s KRAS G12D degrader ASP3082 looked …
- 11/03/2025 - 16:56 -
ESMO 2025 – J&J brings a new Rybrevant use into the fold
… After Johnson & Johnson’s Rybrevant intrigued at ESMO 2024 in colorectal cancer the company now has its eye …
- 10/20/2025 - 12:52 -
Incyte goes pivotal in CDK2
… & ovarian cancers +/- Ibrance, +/- Faslodex; data at ESMO 2024 + atirmociclib (CDK4i) in breast cancer: 28% ORR …
- 10/16/2025 - 12:33 -
J&J goes straight into phase 3 in prostate
… an anti-Steap1 T-cell engager. Still, data presented at ESMO 2024 showed efficacy broadly in line with ARX517 and …
- 09/16/2025 - 14:56 -
J&J’s bladder hope gets its first approval
… cystectomy + cetrelimab, vs cetrelimab Data at ESMO 2024: pCR 42% with TAR-200 + cetrelimab, vs 23% with …
- 09/12/2025 - 10:17 -
Nuvation gets in before Nuvalent
… has 11 to 20-fold selectivity for ROS1 over TRK. In an ESMO 2024 poster Nuvalent put this at a more conservative …
- 06/16/2025 - 13:48
